Previously treated non-small cell lung cancer
Conditions
Interventions
All patients undergo FDG-PET/MRI before and 2, 8 and 16 weeks after initiation of nivolumab therapy.
Sponsors
Third department of internal medicine, Universtiy of Fukui
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Pathologically confirmed advanced non-small cell lung cancer (NSCLC), and one or more prior systemic treatment regimens for advanced NSCLC 2) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 3) Patient with evaluable lesion based on RECIST 4) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Fasting serum glucose levels above 150 mg/dl 2) Pregnant woman 3) Patients with metalic device in their body 4) Patients with claustrophobia 5) Patients with obvious interstitial pneumonia or pulmonary fibrosis in the chest X-ray. 6) Patients with collagen vascular disease or autoimmune diseases 7) Other cases attending physician it is determined unsuitable for registration of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relationship between serial FDG-PET/MRI findings and progression free survival and tumor response. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Association of serial change of FDG-PET/MRI findings with overall survival. 2. To evaluate the FDG-PET/MRI findings of side effect of nivolumab therapy. 3. Association of FDG-PET/MRI findings and PD-L1 expression of lung cancer. | — |
Countries
Japan
Contacts
Public ContactYukihiro Umeda
University of Fukui Third department of internal medicine
Outcome results
None listed